Comparison between Oral Nifedipine and Intravenous Labetalol in Managing Severe Preeclampsia
Oral Nifedipine and Intravenous Labetalol in Managing Severe Preeclampsia
DOI:
https://doi.org/10.54393/pjhs.v6i5.3026Keywords:
Severe Preeclampsia, Oral Nifedipine, Intravenous Labetalol, Hypertensive DisordersAbstract
Hypertensive disorders contribute to significant maternal morbidity and mortality in pregnancy. Immediate treatment is required to avoid serious complications. Objectives: To compare the mean time taken to achieve the target BP with oral nifedipine versus intravenous labetalol in patients with severe preeclampsia. Methods: This quasi-experimental study was conducted at Lady Willington Hospital, Lahore, over six months after taking approval from CPSP, involving 100 patients diagnosed with severe preeclampsia. Participants were divided into two equal groups: Group oral nifedipine and IV labetalol. Study outcome time taken to reach target BP <140/90 mmHg was compared among groups using an independent sample test, with a p-value≤ 0.05 as significant. Results: Target BP was achieved earlier at 43.96 ± 5.93 minutes with oral nifedipine compared to IV labetalol at 48.60 ± 6.80 minutes (p<0.001). Conclusions: It was concluded that the findings strongly support the use of nifedipine as a more effective option for rapidly lowering blood pressure compared to labetalol. Its faster onset of action makes it the preferred choice for achieving timely blood pressure control in patients with severe preeclampsia.
References
Dimitriadis E, Rolnik DL, Zhou W, Estrada-Gutierrez G, Koga K, Francisco RP et al. Pre-Eclampsia. Nature Reviews Disease Primers. 2023 Feb; 9(1): 8. doi: 10.1038/s41572-023-00417-6. DOI: https://doi.org/10.1038/s41572-023-00417-6
Roberts JM. Preeclampsia Epidemiology (Ies) and Pathophysiology (Ies). Best Practice and Research Clinical Obstetrics and Gynaecology. 2024 Feb: 102480. doi: 10.1016/j.bpobgyn.2024.102480. DOI: https://doi.org/10.1016/j.bpobgyn.2024.102480
Macedo TC, Montagna E, Trevisan CM, Zaia V, de Oliveira R, Barbosa CP, Laganà AS, Bianco B. Prevalence of Preeclampsia and Eclampsia in Adolescent Pregnancy: A Systematic Review and Meta-Analysis of 291,247 Adolescents Worldwide Since 1969. European Journal of Obstetrics and Gynecology and Reproductive Biology. 2020 May; 248: 177-86. doi: 10.1016/j.ejogrb.2020.03.043. DOI: https://doi.org/10.1016/j.ejogrb.2020.03.043
Beech A and Mangos G. Management of Hypertension in Pregnancy. Australian Prescriber. 2021 Oct; 44(5): 148. doi: 10.18773/austprescr.2021.039. DOI: https://doi.org/10.18773/austprescr.2021.039
Scheres LJ, Lijfering WM, Groenewegen NF, Koole S, De Groot CJ, Middeldorp S et al. Hypertensive Complications of Pregnancy and Risk of Venous Thromboembolism. Hypertension. 2020 Mar; 75(3): 781-7. doi: 10.1161/HYPERTENSIONAHA.119.14280. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.119.14280
Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA et al. Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement from the American Heart Association. Hypertension. 2022 Feb; 79(2): e21-41. doi: 10.1161/HYP.0000000000000208. DOI: https://doi.org/10.1161/HYP.0000000000000208
Ashworth D, Battersby C, Bick D, Green M, Hardy P, Leighton L et al. A Treatment Strategy with Nifedipine Versus Labetalol for Women with Pregnancy Hypertension: Study Protocol for A Randomized Controlled Trial (Giant PANDA). Trials. 2023 Sep; 24(1): 584. doi: 10.1186/s13063-023-07582-9. DOI: https://doi.org/10.1186/s13063-023-07582-9
Smith N, Kim SK, Goyert G, Lin CH, Rose C, Pitts DA. Nifedipine Outperforms Labetalol: A Comparative Analysis of Hypertension Management in Black Pregnancies. Pregnancy Hypertension. 2024 Sep; 37: 101147. doi: 10.1016/j.preghy.2024.101147. DOI: https://doi.org/10.1016/j.preghy.2024.101147
Kumari M, Thakur S, Singh K, Shekhar S. Comparative Maternal Outcomes of Oral Nifedipine and Intravenous Labetalol for Severe Hypertension During Pregnancy: An Open Label Randomized Controlled Trial. International Journal of Reproduction, Contraception, Obstetrics and Gynaecology. 2020 Jul; 9(7): 2847-52. doi: 10.18203/2320-1770.ijrcog20202720. DOI: https://doi.org/10.18203/2320-1770.ijrcog20202720
Shahnaz I, Ali E, Das S, Hoque IU. A Comparative Study on Efficacy of Intravenous Labetalol and Oral Nifedipine for Control of Blood Pressure in Severe Pre-Eclampsia in A Tertiary Care Hospital. International Journal of Academic Medicine and Pharmacy. 2024; 6(4): 945-51.
Shekhar S, Sharma C, Thakur S, Verma S. Oral Nifedipine or Intravenous Labetalol for Hypertensive Emergency in Pregnancy: A Randomized Controlled Trial. Obstetrics and Gynaecology. 2013 Nov; 122(5): 1057-63. doi: 10.1097/AOG.0b013e3182a9ea68. DOI: https://doi.org/10.1097/AOG.0b013e3182a9ea68
Wiles K, Damodaram M, Frise C. Severe Hypertension in Pregnancy. Clinical Medicine. 2021 Sep; 21(5): e451-6. doi: 10.7861/clinmed.2021-0508. DOI: https://doi.org/10.7861/clinmed.2021-0508
Sinkey RG, Battarbee AN, Bello NA, Ives CW, Oparil S, Tita AT. Prevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: A Comparison of International Guidelines. Current Hypertension Reports. 2020 Sep; 22: 1-0. doi: 10.1007/s11906-020-01082-w. DOI: https://doi.org/10.1007/s11906-020-01082-w
Li L, Xie W, Xu H, Cao L. Oral Nifedipine Versus Intravenous Labetalol for Hypertensive Emergencies During Pregnancy: A Systematic Review and Meta-Analysis. The Journal of Maternal-Fetal and Neonatal Medicine. 2023 Dec; 36(2): 2235057. doi: 10.1080/14767058.2023.2235057. DOI: https://doi.org/10.1080/14767058.2023.2235057
Sahai R, Nidhi A, Ranjan R, Lal S. Comparative Study of Oral Nifedipine Versus Intravenous Labetalol in Severe Hypertension in Pregnancy: A Randomized Controlled Study. International Journal of Obstetrics and Gynaecology Research. 2020; 7(1): 75-80. doi: 10.18231/j.ijogr.2020.016. DOI: https://doi.org/10.18231/j.ijogr.2020.016
Kaur T, Kumari K, Rai P, Gupta V, Pandey S, Saini S. A Comparative Study of Oral Nifedipine and Intravenous Labetalol for Acute Hypertensive Management in Pregnancy: Assessing Feto-Maternal Outcomes in a Hospital-based Randomized Control Trial. International Journal of Maternal and Child Health and AIDS. 2024 May; 13: e011. doi: 10.25259/IJMA_660. DOI: https://doi.org/10.25259/IJMA_660
Nivethana KB, Senthil P, Krupanidhi K. A Comparative Study of IV Labetalol with Oral Nifedipine in Severe Preeclampsia. International Journal of Clinical Obstetrics and Gynaecology. 2020; 4: 388-92. doi: 10.33545/gynae.2020.v4.i1f.491. DOI: https://doi.org/10.33545/gynae.2020.v4.i1f.491
Upendra N, Venkatesh JS, Nair AS, Mohankumar L, Ahmed M, Shetty SP. A Comparative Study on Effectiveness of Oral Labetalol Versus Oral Nifedipine Used in the Treatment of Gestational Hypertension in a Tertiary Care Teaching Hospital. RGUHS Journal of Pharmaceutical Sciences. 2023; 13(2). doi: 10.26463/rjps.13_2_5. DOI: https://doi.org/10.26463/rjps.13_2_5
Donel S, Novri DA, Hamidy Y, Savira M. Effectiveness of Nifedipine, Labetalol, and Hydralazine as Emergency Antihypertension in Severe Preeclampsia: A Randomized Control Trial. F1000Research. 2023 Apr; 11: 1287. doi: 10.12688/f1000research.125944.2. DOI: https://doi.org/10.12688/f1000research.125944.2
Wasim T, Agha S, Saeed K, Riaz A. Oral Nifidepine Versus IV Labetalol in Severe Preeclampsia: A Randomized Control Trial. Pakistan Journal of Medical Sciences. 2020 Sep; 36(6): 1147. doi: 10.12669/pjms.36.6.2591. DOI: https://doi.org/10.12669/pjms.36.6.2591
Deng NJ, Xian-Yu CY, Han RZ, Huang CY, Ma YT, Li HJ et al. Pharmaceutical Administration for Severe Hypertension During Pregnancy: Network Meta-Analysis. Frontiers in Pharmacology. 2023 Jan; 13: 1092501. doi: 10.3389/fphar.2022.1092501. DOI: https://doi.org/10.3389/fphar.2022.1092501
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
